research Tebentafusp-tebn (Kimmtra®) March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research ONKOLOGIA OKULISTYCZNA WCZORAJ I DZIŚ January 2024 in “Wiadomości Lekarskie” Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.